169 related articles for article (PubMed ID: 20686378)
1. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Kotowicz B; Kaminska J; Fuksiewicz M; Kowalska M; Jonska-Gmyrek J; Gawrychowski K; Sobotkowski J; Skrzypczak M; Starzewski J; Bidzinski M
Int J Gynecol Cancer; 2010 May; 20(4):588-92. PubMed ID: 20686378
[TBL] [Abstract][Full Text] [Related]
2. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer.
Fuksiewicz M; Kowalska M; Kotowicz B; Rubach M; Chechlinska M; Pienkowski T; Kaminska J
Clin Chem Lab Med; 2010 Oct; 48(10):1481-6. PubMed ID: 20578967
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor.
Kaminska J; Nowacki MP; Kowalska M; Rysinska A; Chwalinski M; Fuksiewicz M; Michalski W; Chechlinska M
Tumour Biol; 2005; 26(4):186-94. PubMed ID: 16006772
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K
Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
[TBL] [Abstract][Full Text] [Related]
8. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma.
Bender DP; Sorosky JI; Buller RE; Sood AK
Am J Obstet Gynecol; 2003 Jul; 189(1):113-7. PubMed ID: 12861147
[TBL] [Abstract][Full Text] [Related]
9. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
11. Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer.
Guo S; Yang B; Liu H; Li Y; Li S; Ma L; Liu J; Guo W
J Cancer Res Ther; 2017; 13(4):689-692. PubMed ID: 28901315
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers and their prognostic value in adenocarcinoma of the cervix.
Ngan HY; Cheung AN; Lauder IJ; Cheng DK; Wong LC; Ma HK
Tumour Biol; 1998; 19(6):439-44. PubMed ID: 9817971
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
14. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
[TBL] [Abstract][Full Text] [Related]
15. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.
Łukaszewicz-Zając M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Dis Esophagus; 2012 Apr; 25(3):242-9. PubMed ID: 21895853
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
[TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract][Full Text] [Related]
19. [Serum levels and urinary excretion of soluble receptors for tumor necrosis factor (sTNF R) in patients with primary glomerulonephritis].
Kacprzyk F
Pol Arch Med Wewn; 2002 Mar; 107(3):215-21. PubMed ID: 12107979
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer.
Molina R; Filella X; Lejarcegui JA; Pahisa J; Torné A; Rovirosa A; Mellado B; Ordi J; Puig-Tintore LM; Alicarte J; Biete A; Iglesias J
Tumour Biol; 2003; 24(3):156-64. PubMed ID: 14610320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
